Antheia
Antheia, based in Menlo Park, US, uses synthetic biology to unlock nature's medicinal power for next-gen drug discovery.
Founded
2015Antheia, based in Menlo Park, US, uses synthetic biology to unlock nature's medicinal power for next-gen drug discovery.
Antheia, founded in Menlo Park, US, leverages synthetic biology to revolutionize drug discovery and manufacturing. The company's core mission is to unlock nature's medicinal power by surpassing the limitations of conventional methods. Antheia's platform focuses on whole cell engineering to reconstruct complex molecules in yeast, aiming to bring next-generation, plant-inspired medications to market. Their innovative approach targets the pharmaceutical industry, addressing critical issues like drug shortages and the scalability of natural compounds.
Notable figures affiliated with Antheia include experts in synthetic biology and biotechnology. The company has attracted significant investment from leading venture capital firms, underscoring its potential in transforming drug manufacturing. Key achievements include breakthroughs in synthetic biology that enable the production of complex medicinal compounds at scale. Antheia's impact is profound, offering a sustainable and efficient alternative to traditional drug production methods, thereby enhancing the availability and reliability of essential medicines.
Companies similar to Antheia include Think Bioscience, Synthex, Absci and Octant.
Antheia was founded in 2015.
Antheia's headquarters is located in Menlo Park, CA, US.
Antheia's most recent funding round was for $24M (USD) in January 2026.
As of Jan 1, 2026, Antheia has disclosed funding of $221.1M (USD). Undisclosed round amounts are excluded.
Antheia has 63 employees as of Feb 5, 2024.
